



Oncology

**KISQALI<sup>®</sup> (ribociclib)**

[Prescribing information](#)



Oncology

**SANDOSTATIN<sup>®</sup> LAR<sup>®</sup> (octreotide acetate)**

[Prescribing information](#)



Oncology

**TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)**

[Prescribing information](#)



Oncology

**TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma**

[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://prod.pro.novartis.com/uk-en/medicines/oncology>